Pioglitazone-d4 (CAS 1134163-31-7)
See product citations (3)
QUICK LINKS
Pioglitazone-d4 functions as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. It acts by binding to PPARγ, a nuclear receptor that regulates gene expression involved in glucose and lipid metabolism. Upon binding, Pioglitazone-d4 modulates the transcription of target genes, leading to increased insulin sensitivity, enhanced glucose uptake, and decreased hepatic glucose production. Pioglitazone-D4 also exerts anti-inflammatory effects by inhibiting the expression of pro-inflammatory cytokines and adhesion molecules. Pioglitazone-d4 may promote adipocyte differentiation and reduce adipose tissue inflammation. Its mechanism of action involves the activation of PPARγ, which in turn regulates various metabolic and inflammatory pathways at the molecular level.
Pioglitazone-d4 (CAS 1134163-31-7) References
- Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. | Kobayashi, M., et al. 1992. Diabetes. 41: 476-83. PMID: 1318856
- Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. | Hofmann, C., et al. 1991. Endocrinology. 129: 1915-25. PMID: 1915075
- Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase. | Seto-Young, D., et al. 2011. Horm Metab Res. 43: 250-6. PMID: 21321839
- Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner. | Birnbaum, Y., et al. 2011. Basic Res Cardiol. 106: 431-46. PMID: 21360043
- Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. | Aquilante, CL., et al. 2013. Pharmacotherapy. 33: 1000-7. PMID: 23712614
- A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. | Kawaguchi-Suzuki, M., et al. 2014. J Chromatogr B Analyt Technol Biomed Life Sci. 969: 219-23. PMID: 25195022
- Pharmacokinetic Drug Interaction Studies with Enzalutamide. | Gibbons, JA., et al. 2015. Clin Pharmacokinet. 54: 1057-69. PMID: 25929560
- Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males. | Sasaki, T., et al. 2015. Adv Ther. 32: 404-17. PMID: 25975816
- Liquid chromatography and tandem mass spectrometry method for quantitative determination of pioglitazone and its metabolite 5-hydroxy pioglitazone in human plasma. | Chinnalalaiah, R., et al. 2017. Ann Pharm Fr. 75: 105-111. PMID: 27659416
- Autologous fat transplants to deliver glitazone and adiponectin for vasculoprotection. | Sanders, WG., et al. 2017. J Control Release. 264: 237-246. PMID: 28867378
- Co-stabilization of pioglitazone HCL nanoparticles prepared by planetary ball milling: in-vitro and in-vivo evaluation. | Alshora, DH., et al. 2020. Pharm Dev Technol. 25: 845-854. PMID: 32174213
- Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. | Kawamori, R., et al. 1998. Diabetes Res Clin Pract. 41: 35-43. PMID: 9768370
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Pioglitazone-d4, 1 mg | sc-219625 | 1 mg | $347.00 |